OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2‐year genistein administration
Journal of Bone and Mineral Research, 2008•academic.oup.com
Introduction: RANKL and its decoy receptor osteoprotegerin (OPG) constitute a complex
physiological mediator system involved in the regulation of bone resorption and may be
responsible for the homeostatic mechanism of normal bone remodeling. Genistein, an
isoflavone representing 1–5% of total phytoestrogen content in soybean products, may
positively regulate cellular bone metabolism, but its mechanism of action on bone is not yet
fully understood. Materials and Methods: We studied the serum levels of both soluble …
physiological mediator system involved in the regulation of bone resorption and may be
responsible for the homeostatic mechanism of normal bone remodeling. Genistein, an
isoflavone representing 1–5% of total phytoestrogen content in soybean products, may
positively regulate cellular bone metabolism, but its mechanism of action on bone is not yet
fully understood. Materials and Methods: We studied the serum levels of both soluble …
Abstract
Introduction: RANKL and its decoy receptor osteoprotegerin (OPG) constitute a complex physiological mediator system involved in the regulation of bone resorption and may be responsible for the homeostatic mechanism of normal bone remodeling. Genistein, an isoflavone representing 1–5% of total phytoestrogen content in soybean products, may positively regulate cellular bone metabolism, but its mechanism of action on bone is not yet fully understood.
Materials and Methods: We studied the serum levels of both soluble RANKL (sRANKL) and OPG and the sRANKL/OPG ratio in 389 postmenopausal women (age, 49–67 yr) with a femoral neck BMD <0.795 g/cm2 and no significant comorbid conditions after 24‐mo therapy with genistein, (n = 198; 54 mg/d) or placebo (n = 191). Both intervention and placebo contained calcium and vitamin D3. All patients received dietary instruction in an isocaloric fat‐reduced diet.
Results: In comparison with placebo, sRANKL level was lower (p < 0.001 versus placebo) and OPG higher in genistein recipients (p < 0.001 versus placebo) at 1 and 2 yr, respectively. Moreover, at the end of 24 mo, genistein produced a significant reduction in the sRANKL/OPG ratio compared with placebo (genistein = −0.021, 95% CI, −0.020 to −0.022; placebo = +0.004, 95% CI, 0.003–0.005; difference = −0.020, 95% CI, −0.015 to −0.025, p < 0.001).
Conclusions: Our findings suggest that genistein plus calcium and vitamin D3 as part of a healthy diet is able to positively modulate bone turnover in a cohort of osteopenic, postmenopausal women and improve sRANKL‐OPG balance after 24 mo of treatment.
Oxford University Press以上显示的是最相近的搜索结果。 查看全部搜索结果